Kotoulas Serafeim Chrysovalantis, Tsiouprou Ioanna, Fouka Eva, Pataka Athanasia, Papakosta Despoina, Porpodis Konstantinos
Pulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. Papanikolaou'' General Hospital, Exohi, 57010 Thessaloniki, Greece.
J Pers Med. 2022 Jan 26;12(2):165. doi: 10.3390/jpm12020165.
Omalizumab is the first monoclonal antibody that was globally approved as a personalized treatment option for patients with moderate-to-severe allergic asthma. This review summarizes the knowledge of almost two decades of use of omalizumab to answer some important everyday clinical practice questions, concerning its efficacy and safety and its association with other asthma-related and drug-related parameters. Evidence suggests that omalizumab improves asthma control and reduces the incidence and frequency of exacerbations in patients with severe allergic asthma. Omalizumab is also effective in those patients in reducing corticosteroid use and healthcare utilization, while it also seems to improve lung function. Several biomarkers have been recognized in predicting its efficacy in its target group of patients, while the optimal duration for evaluating its efficacy is between 16 and 32 weeks.
奥马珠单抗是首个在全球获批用于中重度过敏性哮喘患者的个性化治疗选择的单克隆抗体。本综述总结了近二十年来使用奥马珠单抗的相关知识，以回答一些日常临床实践中的重要问题，涉及药物的疗效和安全性及其与其他哮喘相关和药物相关参数的关联。有证据表明，奥马珠单抗可改善哮喘控制，降低重度过敏性哮喘患者发作的发生率和频率。奥马珠单抗在减少这些患者使用皮质类固醇和医疗资源利用方面也有效，同时似乎还能改善肺功能。在预测其对目标患者群体的疗效方面，已识别出几种生物标志物，而评估其疗效的最佳持续时间为16至32周。
